BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. ROIV
6. AAPL
7. HOOD
8. QCOM
9. ACN
10. AZN

Go back to BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
(NASDAQ: BBIO) Delayed: 74.76 -0.08 (0.11%)
Previous Close $74.84    52 Week High $ 
Open $73.60    52 Week Low $ 
Day High $76.34    P/E N/A 
Day Low $73.26    EPS $ 
Volume 2,120,947